LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: Brown fat: atypical locations and appearances encountered in PET/CT.

    Paidisetty, Sanjay / Blodgett, Todd M

    AJR. American journal of roentgenology

    2009  Volume 193, Issue 2, Page(s) 359–366

    Abstract: Objective: The purpose of this article is to review the physiology and describe the typical and atypical presentations of brown fat on (18)F-FDG PET.: Conclusion: The presence of brown fat on FDG PET has the potential to lead to misinterpretation and ...

    Abstract Objective: The purpose of this article is to review the physiology and describe the typical and atypical presentations of brown fat on (18)F-FDG PET.
    Conclusion: The presence of brown fat on FDG PET has the potential to lead to misinterpretation and unneeded invasive tests, which can be avoided by using measures such as ensuring the patient is warm, reducing FDG uptake in brown fat before the procedure, and correlating PET uptake to a specific anatomic location with PET/CT fusion imaging.
    MeSH term(s) Adipose Tissue, Brown/diagnostic imaging ; Adipose Tissue, Brown/metabolism ; Adult ; Diagnosis, Differential ; Female ; Fluorodeoxyglucose F18/pharmacokinetics ; Humans ; Lymph Nodes/metabolism ; Male ; Middle Aged ; Muscle, Skeletal/metabolism ; Neck ; Neoplasms/diagnosis ; Neoplasms/metabolism ; Positron-Emission Tomography ; Radiopharmaceuticals/pharmacokinetics ; Tomography, X-Ray Computed
    Chemical Substances Radiopharmaceuticals ; Fluorodeoxyglucose F18 (0Z5B2CJX4D)
    Language English
    Publishing date 2009-07-16
    Publishing country United States
    Document type Journal Article
    ZDB-ID 82076-3
    ISSN 1546-3141 ; 0361-803X ; 0092-5381
    ISSN (online) 1546-3141
    ISSN 0361-803X ; 0092-5381
    DOI 10.2214/AJR.08.2081
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ue I Zs.57: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration.

    Gordon, Adam J / Kavanagh, Greg / Krumm, Margaret / Ramgopal, Rajeev / Paidisetty, Sanjay / Aghevli, Minu / Goodman, Francine / Trafton, Jodie / Liberto, Joseph

    Psychology of addictive behaviors : journal of the Society of Psychologists in Addictive Behaviors

    2011  Volume 25, Issue 2, Page(s) 215–224

    Abstract: Opioid dependence is a chronic, relapsing disorder that deleteriously influences the health of those afflicted. Sublingual buprenorphine opioid agonist treatment (OAT) has been shown to be safe, effective, and cost-effective for the treatment of opioid ... ...

    Abstract Opioid dependence is a chronic, relapsing disorder that deleteriously influences the health of those afflicted. Sublingual buprenorphine opioid agonist treatment (OAT) has been shown to be safe, effective, and cost-effective for the treatment of opioid dependence in nonspecialized, office-based settings, including the Veterans Health Administration (VHA). We sought to examine and describe provider-, facility-, and system-level barriers and facilitators to implementing buprenorphine therapy within the VHA. From June 2006 to October 2007, we conducted semistructured telephone interviews of key personnel at a national sample of VHA facilities with high prevalence of opioid dependence and without methadone OAT programs. Sites were categorized based on the number of veterans receiving buprenorphine prescriptions: More Buprenorphine (MB, >40 prescriptions, 5 sites), Some Buprenorphine (SB, 5-40 prescriptions, 3 sites), and No Buprenorphine (NB, 0-5 prescriptions, 9 sites). Interviews were taped, transcribed, and coded; consensus of coding themes was reached; and data were evaluated using grounded theory. Sixty-two staff members were interviewed. For NB sites, perceived patient barriers included lack of need and attitudes/stigma associated with opioid dependence. Provider barriers included lack of interest, stigma toward the population, and lack of education about buprenorphine-OAT. Prominent facilitators at MB sites included having established need, provider interest, and resources/time available for buprenorphine-OAT. The presence of a champion/role-model for buprenorphine care greatly facilitated its implementation. We conclude that factors that enable or impede buprenorphine-OAT vary by facility. Strategies and policies to encourage implementation of buprenorphine should be adaptable and target needs of each facility.
    MeSH term(s) Attitude of Health Personnel ; Buprenorphine/therapeutic use ; Health Services Accessibility ; Health Services Needs and Demand ; Humans ; Narcotic Antagonists/therapeutic use ; Opioid-Related Disorders/prevention & control ; United States ; United States Department of Veterans Affairs ; Veterans Health
    Chemical Substances Narcotic Antagonists ; Buprenorphine (40D3SCR4GZ)
    Language English
    Publishing date 2011-06
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2101111-4
    ISSN 1939-1501 ; 0893-164X
    ISSN (online) 1939-1501
    ISSN 0893-164X
    DOI 10.1037/a0022776
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top